Outdated Regulatory System Slows Technical Progress, Investigator Charges
Executive Summary
Allowing other stem cell companies to use the protocol honed by Neuralstem instead of starting at square one would speed promising therapies to ALS patients and advance the field, researchers and patient advocates argued at FDA’s hearing on ALS drug development and regulation.